CAAS Capital Management’s Precigen PGEN Stock Holding History

CAAS Capital Management’s Portfolio PGEN Stock Details PGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-288,169	Closed	-$305K	–	814
2023 Q1	$305K	Buy	+288,169	New	+$415K	0.02%	483

Other funds holding PGEN

PCM

Patient Capital Management Baltimore, Maryland $2.74B AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CAAS Capital Management's PGEN Position: Q2 2023 in Review

CAAS Capital Management sold out of Precigen (PGEN) in Q2 2023, closing a stake of 288,169 shares — an estimated $305K sold.

CAAS Capital Management first reported a position in PGEN in Q1 2023 and held it in 1 quarter. The position peaked at $305K in Q1 2023. 138 funds tracked by Wall St. Rank hold PGEN as of Q2 2023.

CAAS Capital Management reported no remaining Precigen position as of Q2 2023 after selling out during the quarter.
CAAS Capital Management sold 288,169 Precigen shares in Q2 2023, an estimated $305K.
CAAS Capital Management first reported a position in Precigen in Q1 2023 and held it in 1 quarter.
CAAS Capital Management's Precigen position peaked at $305K in Q1 2023.
138 funds tracked by Wall St. Rank held Precigen as of Q2 2023.

Based on CAAS Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.